Nuveen Asset Management LLC Sells 50,790 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Nuveen Asset Management LLC decreased its stake in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 22.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 179,200 shares of the company's stock after selling 50,790 shares during the quarter. Nuveen Asset Management LLC owned 0.39% of Omnicell worth $7,978,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC raised its position in shares of Omnicell by 51.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock worth $35,000 after purchasing an additional 273 shares during the period. Johnson Financial Group Inc. acquired a new stake in shares of Omnicell during the fourth quarter worth about $37,000. Van ECK Associates Corp raised its position in shares of Omnicell by 47.0% during the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company's stock worth $44,000 after purchasing an additional 315 shares during the period. Headlands Technologies LLC acquired a new stake in shares of Omnicell during the fourth quarter worth about $53,000. Finally, First Horizon Advisors Inc. raised its position in shares of Omnicell by 36.3% during the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock worth $59,000 after purchasing an additional 355 shares during the period. Institutional investors and hedge funds own 97.70% of the company's stock.

Omnicell Stock Down 0.6%

OMCL stock traded down $0.17 during mid-day trading on Monday, reaching $30.20. The company had a trading volume of 633,067 shares, compared to its average volume of 570,129. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. The stock has a 50 day simple moving average of $30.34 and a two-hundred day simple moving average of $37.85. The company has a market capitalization of $1.41 billion, a price-to-earnings ratio of 111.86, a PEG ratio of 7.53 and a beta of 0.78. Omnicell, Inc. has a 52 week low of $22.66 and a 52 week high of $55.75.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, topping analysts' consensus estimates of $0.16 by $0.10. The business had revenue of $269.67 million for the quarter, compared to analyst estimates of $260.18 million. Omnicell had a return on equity of 3.82% and a net margin of 1.13%. The firm's revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.03 EPS. As a group, equities analysts predict that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently commented on OMCL. Benchmark dropped their price target on Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Bank of America lifted their target price on Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research report on Friday, May 23rd. Wells Fargo & Company reissued an "overweight" rating and issued a $37.00 target price (up previously from $35.00) on shares of Omnicell in a research report on Friday, May 23rd. Piper Sandler reissued an "overweight" rating on shares of Omnicell in a research report on Friday, May 23rd. Finally, Wall Street Zen raised Omnicell from a "hold" rating to a "buy" rating in a research report on Tuesday, May 20th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Omnicell has a consensus rating of "Moderate Buy" and a consensus target price of $44.83.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.